ДБДмитрий Евгеньевич Богачев

Дмитрий Евгеньевич Богачев

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Дмитрий Евгеньевич Богачев has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The role of functional diagnostics methods in detecting right ventricular thrombosis and pulmonary artery thromboembolism in a patient with pneumonia. Clinical observation

    by T. D. Malchenko, Ya. N. Shoikhet, I. Ya. Tseimakh, T. A. Kornilova, D. E. Bogachev

    Purpose of the study : exchange of experience in the diagnosis and treatment of severe pneumonia complicated by right ventricular thrombosis and the formation of an acute pulmonary heart. Materials and methods . The clinical observation of the patient during inpatient treatment is presented on the basis of diagnostic studies, a comprehensive study of the medical history and an archive of medical documents. Results . A clinical case of a 19-year-old patient is presented, in whom the initial symptoms of septic pneumonia were regarded as a manifestation of acute respiratory viral infection, but subsequently signs of rapidly increasing respiratory failure and manifestations of septic shock appeared. Conclusion . Severe pneumonia remains a difficult disease to treat, requiring a multidisciplinary approach to diagnose and determine patient management tactics.

  • Efficacy of combined folic acid, cyanocobalamin, and pyridoxine hydrochloride therapy in the comprehensive management of pneumonia associated with COVID-19

    by I. Ya. Tseymakh, D. E. Bogachev, A. Yu. Zhbanov, A. N. Karkavina, T. A. Kornilova

    Aim. To evaluate the clinical efficacy and the effect on serum homocysteine levels of combined folic acid, cyanocobalamin, and pyridoxine hydrochloride therapy in the comprehensive treatment of pneumonia in hospitalized patients with COVID-19.Materials and methods. An open-label, prospective, comparative study included 75 hospitalized patients with moderate to severe pneumonia associated with COVID-19 confirmed by detection of SARS-CoV-2 RNA in the respiratory tract. The main group consisted of 28 patients who received micronutrient therapy with 30 mg/day of folic acid plus cyanocobalamin and pyridoxine in addition to standard treatment. The comparison group comprised 47 patients who did not receive additional micronutrient therapy. The Charlson Comorbidity Index was 1.14 ± 0.93 in the main group and 0.47 ± 0.69 in the comparison group (p ≤ 0.001). Disease severity before and after treatment was assessed using the NEWS, qSOFA, 4C Mortality, and WHO Ordinal scales. Chest computed tomography (CT) was performed. Laboratory parameters included complete blood count, serum levels of C-reactive protein (CRP), ferritin, lactate dehydrogenase (LDH), homocysteine, triglycerides, and low- and high-density lipoprotein cholesterol (LDL, HDL).Results. In the main group, elimination period of SARS-CoV-2 RNA was achieved in 7.2 ± 3.4 days versus 15.6 ± 6.3 days in the comparison group (p < 0.001). After micronutrient therapy, disease severity decreased according to qSOFA and 4C Mortality scales. The main group showed a reduction in the total pneumonia volume from 32.0 (19.8–73.0)% to 26.5 (11.8–50.8)% (p = 0.035) and a reduction in the volume of parenchymal consolidation from 9.0 (0.0–37.3)% to 2.0 (0.0–17.0)% (p = 0.027). In the comparison group, there was no decrease in the total volume of lung involvement, and the area of parenchymal consolidation increased. These clinical and CT findings were associated with reductions in CRP, serum homocysteine, and LDL levels. Multiple linear regression models demonstrated that administration of the folic acid, cyanocobalamin, and pyridoxine hydrochloride combination shortened the elimination period of SARS-CoV-2 RNA from the respiratory tract (regression coefficient β = –8.648 ± 1.781; p < 0.001) and contributed to a decrease in parenchymal consolidation volume after treatment (β = –13.492 ± 4.834; p = 0.011), with the effect also linked to baseline LDH levels (β = 0.0235 ± 0.00857; p = 0.008) and patient age (β = 0.167 ± 0.0608; p = 0.008).Conclusion. The use of folic acid, cyanocobalamin, and pyridoxine hydrochloride in the comprehensive management of patients with COVID-19-associated pneumonia is associated with a shorter SARS-CoV-2 RNA elimination period from the upper respiratory tract, a more pronounced reduction in disease severity, and a decreased extent of lung parenchymal consolidation. These effects coincide with lower serum homocysteine levels.

  • Diagnosis and treatment of right ventricular thrombosis in a female patient with pulmonary thromboembolism associated with severe pneumonia (Case report)

    by Altay State Medical University, T.D. Malchenko, I.YA. Tseimakh, D.E. Bogachev, Т.а. Kornilova, Barnaul City Hospital No. 5, M.е. Tseimakh

    Introduction. Right ventricular (RV) thrombosis is a rare life-threatening complication of right heart failure developing amid venous thromboembolic complications and severe lower respiratory tract infections. Aim. Exchange of experiences in the diagnosis and treatment of patients with RV thrombosis associated with severe pneumonia. Materials and methods. We studied a history of the inpatient and the archive of medical records, including the results of lab tests, functional diagnostics and radiologic imaging. Results. The article presents a case report of a 19-year-old female patient, in whom the clinical picture of acute right heart failure and RV thrombosis occurred amid severe pneumonia. Conclusion. Timely diagnosis and treatment of acute right heart failure, pulmonary thromboembolism, and RV thrombosis can improve outcomes and reduce mortality in patients with severe pneumonia.

  • The effect of the CD4+ T cell subset and anti-tubercular therapy on SARS-CoV-2 clearance in patients with COVID-19 and tuberculosis co-infection

    by I.YA. Tseymakh, A.P. Semitko, D.E. Bogachev, Ya.A. Dauletova, A.A. Shmakova, Barnaul Altai Regional Tuberculosis Dispensary

    Introduction. The coronavirus disease (COVID-19) pandemic has prompted the study of problems of comorbidities, including widespread and highly pathogenic comorbid infectious diseases. Tuberculosis continues to be major infectious disease in terms of social life and epidemiology that can have a negative impact on the outcomes of patients with COVID-19 and other infectious diseases, including because of the association of pathogenetic mechanisms of these infectious diseases is still unclear. The study of risk factors for adverse outcomes of tuberculosis and COVID-19 co-infection will improve managing these diseases. Aim. To evaluate the impact of changes in immunocompetent cell subsets and specific treatment regimens on SARS-CoV-2 clearance in the respiratory tract of patients with COVID-19 and tuberculosis co-infection. Materials and methods. In a retrospective cohort clinical study we have analyzed the clinical characteristics and duration of elimination of coronavirus (SARS-CoV-2) from the respiratory tract of 76 hospitalized patients with COVID-19 and active tuberculosis. The first group included 37 patients with COVID-19 and active pulmonary or extrapulmonary tuberculosis without signs of lymphogenous or hematogenous spread of Mycobacterium tuberculosis infection (TB P/EP). The second group included 39 patients with COVID-19 and disseminated tuberculosis (DTB). Results. When constructing multiple regression models, the CD4+ count less than 80 cells/µl was the strongest determinant of delayed elimination of SARS-CoV-2 from the respiratory tract with a regression coefficient (β ± m) of 21.762 ± 6.250 (p = 0.002) and 10.853 ± 4.220 (p = 0.015) in the first and second groups, respectively. In combination with the duration of anti-tubercular therapy, antiretroviral therapy, anemia, and platelet count, these factors made it possible to predict a 68.1% variances in the duration of elimination of SARS-CoV-2 from the respiratory tract of patients with TB P/EP, and a 42.7% variances of this indicator in patient with COVID-19 and DTB co-infection. Conclusion. A decrease in the CD4+ count less than 80 cells/µl, the duration of the intensive phase of anti-tubercular therapy, antiretroviral therapy, anemia, peripheral blood platelet count have a comprehensive impact on prolongation of SARS-CoV-2 elimination from the respiratory tract of patients with COVID-19 and tuberculosis co-infection.

  • Open Access

    Impact of correction of homocisteinemia on clinical outcomes of lung damage associated with COVID-19 coronavirus infection

    by I. Ya. Tseimakh, D. E. Bogachev, G. I. Kostuchenko, A. N. Mamaev, T. A. Kornilova, I. S. Shemyakina, A. E. Tseimakh, Ya. N. Shoikhet, И. Я. Цеймах, Я. Н. Шойхет

    Aim. To assess the effect of serum homocysteine levels on treatment outcomes in patients with COVID19-associated lung damage, depending on the use of folic acid in complex treatment.Materials and methods. An open, prospective comparative study included 71 hospitalized adult patients with COVID-19-associated lung disease who did not require mechanical ventilation. The main group included 51 patients who received folic acid 15 mg per day in a complex treatment in a fixed combination with pyridoxine hydrochloride and cyanocobalamin. The comparison group included 20 patients in whose therapy folic acid was not used.Results. The use of folic acid was accompanied by a decrease in serum homocysteine concentration by 2.120 (-0.230; 3.680) µmol/L (p=0.004). When constructing a logistic regression model, the effect of a decrease in serum homocysteine (OR 1.289; 95% CI 1.026‒1.620; p=0.029), methylenetetrahydrofolate reductase MTHFR C677T genotype (OR 10.897; 95% CI 1.240‒95.772; p=0.031) on the achievement of 7th day of hospitalization, the cessation of isolation of SARS-CoV-2 virus RNA from the respiratory tract. Multiple linear regression analysis showed an association between the duration of hypoxemic respiratory failure, determined with SaO2≤93%, with the degree of change in serum homocysteine concentration after treatment, single nucleotide polymorphisms of methylenetetrahydrofolate reductase MTHFR C677T, methionine synthase MTR A2756G and methionine synthase reductase MTRR A66G, initial volume of lung damage ≥50% according to CT data, indicators of D-dimers, C-reactive protein, hemoglobin, platelets, concomitant hypertension, diabetes mellitus (R=0.699; R2=0.489; p=0.005).Conclusion. The dynamics of the decrease in serum homocysteine after treatment is an important predictor of the cessation of isolation from the respiratory tract of the SARS-CoV-2 virus RNA on the 7th day of treatment, reducing the duration of hypoxemic respiratory failure in patients with lung damage associated with COVID-19 infection.


  • Open Access

    DIAGNOSIS OF SARCOIDOSIS FIRST MANIFESTED BY EYE LESIONS (CLINICAL OBSERVATION)

    by Ирина Яковлевна Цеймах, Дмитрий Евгеньевич Богачев, Ирина Сергеевна Шемякина, Татьяна Александровна Корнилова, Ирина Петровна Крамарь, Иван Александрович Выходцев, Irina Ya. Tseimakh, Barnaul City Hospital No. 5

    Бюллетень медицинской науки Журнал «Бюллетень медицинской науки» основан в 2017 году и является официальным научным изданием Алтайского государственного медицинского университета. Издание публикует статьи и обзоры аспирантов и ведущих специалистов, материалы оригинальных исследований в области экспериментальной и клинической медицины, описания клинических случаев, научные обзоры и дискуссии, способствует росту научного потенциала и профессионализма врачебного сообщества.» Журнал АГМУ «Бюллетень медицинской науки» — это электронный научно-практический медицинский рецензируемый журнал Алтайского государственного медицинского университета. Журнал публикует оригинальные исследования, описания клинических случаев, научные обзоры и дискуссии.

  • Open Access

    Effect of folic acid in patients with lung damage caused by coronavirus SARS-CoV-2

    by I.Ya. Tseimakh, Altai State Medical University, G.I. Kostyuchenko, D.E. Bogachev, O.A. Zubova, V.K. Konovalov, T.A. Kornilova, A.G. Kharlova, A.E. Tseimakh, Ya.N. Shoikhet, et al.